Cargando…

Neoadjuvant Endocrine Therapy in Breast Cancer Management: State of the Art

SIMPLE SUMMARY: Over the last ten years, neoadjuvant endocrine therapy (NET) has been increasingly investigated and has gained recognition. NET should not only be used to allow surgery or to improve breast-conserving surgery rates in patients not eligible for NCT, but also as a research tool for the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lerebours, Florence, Cabel, Luc, Pierga, Jean-Yves
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7926493/ https://www.ncbi.nlm.nih.gov/pubmed/33670042 http://dx.doi.org/10.3390/cancers13040902

Ejemplares similares

Plasma thymidine kinase 1 activity and outcome of ER+ HER2− metastatic breast cancer patients treated with palbociclib and endocrine therapy
por: Cabel, Luc, et al.
Publicado: (2020)

Early metabolic response of breast cancer to neoadjuvant endocrine therapy: comparison to morphological and pathological response
por: Boughdad, Sarah, et al.
Publicado: (2020)

Circulating Tumor Cells in Early Breast Cancer
por: Thery, Laura, et al.
Publicado: (2019)

ESR1 Mutation Detection and Dynamics in Meningeal Carcinomatosis in Breast Cancer
por: Carausu, Marcela, et al.
Publicado: (2019)

State of the art in neoadjuvant therapy of breast cancer
por: Minckwitz, Gunter von, et al.
Publicado: (2013)

Predictive factors of 5-year relapse-free survival in HR+/HER2- breast cancer patients treated with neoadjuvant endocrine therapy: pooled analysis of two phase 2 trials
por: Lerebours, Florence, et al.
Publicado: (2020)

The Present and Future of Neoadjuvant Endocrine Therapy for Breast Cancer Treatment
por: Martí, Covadonga, et al.
Publicado: (2021)

Clinical utility of circulating tumor cells: an update
por: Vasseur, Antoine, et al.
Publicado: (2020)

Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer
por: Tanguy, Marie-Laure, et al.
Publicado: (2018)

Impact of time to local recurrence on the occurrence of metastasis in breast cancer patients treated with neoadjuvant chemotherapy: A random forest survival approach
por: Laas, Enora, et al.
Publicado: (2019)

No Impact of Smoking Status on Breast Cancer Tumor Infiltrating Lymphocytes, Response to Neoadjuvant Chemotherapy and Prognosis
por: Simon, Vanille, et al.
Publicado: (2020)

Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives
por: Caparica, Rafael, et al.
Publicado: (2019)

Neoadjuvant endocrine therapy in breast cancer: current role and future perspectives
por: Barroso-Sousa, Romualdo, et al.
Publicado: (2016)

Neoadjuvant Endocrine Therapy in Breast Cancer: Current Knowledge and Future Perspectives
por: Barchiesi, Giacomo, et al.
Publicado: (2020)

Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort
por: Hamy, Anne-Sophie, et al.
Publicado: (2018)

Impact of Adjuvant Chemotherapy on Breast Cancer Survival: A Real-World Population
por: Rossi, Lea, et al.
Publicado: (2015)

Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort
por: Hamy-Petit, Anne-Sophie, et al.
Publicado: (2016)

Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy
por: Bonsang-Kitzis, Hélène, et al.
Publicado: (2015)

Prognostic value of the Residual Cancer Burden index according to breast cancer subtype: Validation on a cohort of BC patients treated by neoadjuvant chemotherapy
por: Hamy, Anne-Sophie, et al.
Publicado: (2020)

Neoadjuvant Endocrine Therapy (NET) in breast cancer – COVID setting
por: Bardoli, Antonio, et al.
Publicado: (2022)

Correction: Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy
por: Bonsang-Kitzis, Hélène, et al.
Publicado: (2016)

Neoadjuvant endocrine therapy in ER-positive breast cancer: evolution, indication, and tailored treatment strategy
por: Jeong, Hyehyun, et al.
Publicado: (2023)

Cancer Treatment–Induced Bone Loss (CTIBL): State of the Art and Proper Management in Breast Cancer Patients on Endocrine Therapy
por: Diana, Anna, et al.
Publicado: (2021)

Surgical Management of Axilla Following Neoadjuvant Endocrine Therapy
por: Murphy, Brenna M., et al.
Publicado: (2021)

Association of Endocrine Therapy for HR+/ERBB2+ Metastatic Breast Cancer With Survival Outcomes
por: Carausu, Marcela, et al.
Publicado: (2022)

Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609)
por: Liang, Xu, et al.
Publicado: (2018)

MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study
por: Tabouret, Emeline, et al.
Publicado: (2016)

Update on inflammatory breast cancer
por: Lerebours, Florence, et al.
Publicado: (2005)

Changes in Recurrence Score by neoadjuvant endocrine therapy of breast cancer and their prognostic implication
por: Ueno, Takayuki, et al.
Publicado: (2019)

Multidisciplinary Approach to Neoadjuvant Endocrine Therapy in Breast Cancer: A Comprehensive Review
por: Reinert, Tomás, et al.
Publicado: (2016)

Circulating tumor cells in breast cancer
por: Bidard, Francois-Clement, et al.
Publicado: (2016)

Determination of breast cancer prognosis after neoadjuvant chemotherapy: comparison of Residual Cancer Burden (RCB) and Neo-Bioscore
por: Laas, Enora, et al.
Publicado: (2021)

PELICAN-IPC 2015-016/Oncodistinct-003: A Prospective, Multicenter, Open-Label, Randomized, Non-Comparative, Phase II Study of Pembrolizumab in Combination With Neo Adjuvant EC-Paclitaxel Regimen in HER2-Negative Inflammatory Breast Cancer
por: Bertucci, Alexandre, et al.
Publicado: (2020)

Neoadjuvant chemotherapy in advanced-stage ovarian cancer – state of the art
por: Margioula-Siarkou, Chrysoula, et al.
Publicado: (2022)

Neoadjuvant immunotherapy for non–small cell lung cancer: State of the art
por: Kang, Jin, et al.
Publicado: (2021)

Neoadjuvant treatment of biliary tract cancer: state-of-the-art and new perspectives
por: Imperatori, Marco, et al.
Publicado: (2016)

Approaching Neoadjuvant Therapy in the Management of Early-Stage Breast Cancer
por: Hyder, Tara, et al.
Publicado: (2021)

Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool
por: Chia, Y H, et al.
Publicado: (2010)

Time-Dependent Prognostic Impact of Circulating Tumor Cells Detection in Non-Metastatic Breast Cancer: 70-Month Analysis of the REMAGUS02 Study
por: Bidard, François-Clément, et al.
Publicado: (2013)

The Prognostic Value of Lymph Node Involvement after Neoadjuvant Chemotherapy Is Different among Breast Cancer Subtypes
por: Laot, Lucie, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dll7hjc8vm47qs5ghi4amu483g